Trastuget®
Therapeutic Segment:
Breast Cancer
Generic Name:
Trastuzumab
Indication
- 440MG
Trastuget (Trastuzumab) is indicated for:
Adjuvant Breast Cancer
Trastuget (Trastuzumab) is indicated for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature) breast cancer:
• as part of a treatment regimen consisting of doxorubicin, clophosphamide, and either paclitaxel or docetaxel.
• as part of a treatment regimen with docetaxel and carboplatin.
• as a single agent following multi-modality anthracycline based therapy.
Metastatic Breast Cancer
• In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer
• As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease.
Metastatic Gastric Cancer
• in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease.